Ad Header



The Pulse of the Pharmaceutical Industry

Gilead’s new HIV drug shows lower side-effects over longer term

Written by: | | Dated: Thursday, October 22nd, 2015

Drugmaker Gilead Sciences Inc said data from a late-stage study showed that its experimental drug, Genvoya, showed reduced side-effects compared with an older version of the drug in treating HIV-infected patients over a longer term.

The company said Genvoya was as good as Stribild, which is the older version, after 96 weeks of treatment and had lesser side-effects on patients’ kidneys and bones.

Genvoya, which is developed from Stribild by replacing one part of the four-drug cocktail, has already received positive opinions from European health regulators.

The company’s marketing application in Europe was supported by two late-stage studies that showed the same benefit, but over 48 weeks of treatment.

Stribild raked in sales of $803 million in the first half of the year, according to a regulatory filing from the company.

Gilead shares were up marginally at $102 premarket. Up to Wednesday’s close, the stock had gained about 8 percent this year.



(Reporting by Vidya L Nathan in Bengaluru; Editing by Anil D’Silva)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom